

1 Joseph R. Re (Bar No. 134479)  
2 joseph.re@knobbe.com  
3 Stephen C. Jensen (Bar No. 149894)  
4 steve.jensen@knobbe.com  
5 Perry D. Oldham (Bar No. 216016)  
6 perry.oldham@knobbe.com  
7 Stephen W. Larson (Bar No. 240844)  
8 stephen.larson@knobbe.com  
9 KNOBBE, MARTENS, OLSON & BEAR, LLP  
10 2040 Main Street, Fourteenth Floor  
11 Irvine, CA 92614  
12 Telephone: (949) 760-0404 Facsimile: (949) 760-9502

13 Adam B. Powell (Bar No. 272725)  
14 adam.powell@knobbe.com  
15 KNOBBE, MARTENS, OLSON & BEAR, LLP  
16 12790 El Camino Real  
17 San Diego, CA 92130  
18 Telephone: (858) 707-4000 Facsimile: (858) 707-4001

19 Attorneys for Plaintiffs,  
20 Masimo Corporation and Cercacor Laboratories, Inc.

21 **IN THE UNITED STATES DISTRICT COURT**  
22 **FOR THE CENTRAL DISTRICT OF CALIFORNIA**  
23 **SOUTHERN DIVISION**

24 MASIMO CORPORATION, ) Case No. 8:20-cv-00048-JVS-JDE  
25 a Delaware corporation; and )  
26 CERCACOR LABORATORIES, INC., ) **SECOND AMENDED**  
27 a Delaware corporation ) **COMPLAINT FOR**  
28 Plaintiffs, ) **(1) PATENT INFRINGEMENT**  
v. ) **(2) TRADE SECRET**  
APPLE INC., a California corporation ) **MISAPPROPRIATION**  
**(3) CORRECTION OF**  
**INVENTORSHIP AND**  
**(4) OWNERSHIP OF PATENTS**  
Defendant. ) **DEMAND FOR JURY TRIAL**  
Hon. James V. Selna

**REDACTED VERSION OF DOCUMENT  
PROPOSED TO BE FILED UNDER SEAL**

1 Plaintiffs MASIMO CORPORATION (“Masimo”) and CERCACOR  
2 LABORATIES, INC. (“Cercacor”) hereby complain of Defendant APPLE INC.  
3 (“Apple”), and allege as follows:

4 **I. THE PARTIES**

5 1. Plaintiff Masimo is a Delaware corporation having its principal  
6 place of business at 52 Discovery, Irvine, California 92618.

7 2. Plaintiff Cercacor is a Delaware corporation having its principal  
8 place of business at 15750 Alton Pkwy, Irvine, California 92618.

9 3. Upon information and belief, Defendant Apple is a California  
10 corporation having a principal place of business at One Apple Park Way,  
11 Cupertino, California, 95014.

12 **II. JURISDICTION AND VENUE**

13 4. This civil action includes claims for patent infringement arising  
14 under the patent laws of the United States, 35 U.S.C. §§ 100, *et seq.*, more  
15 particularly, 35 U.S.C. §§ 271 and 281. This civil action includes claims for  
16 correction of inventorship of certain United States patents arising under the  
17 patent law of the United States, more particularly 35 U.S.C. § 256. This  
18 Complaint further alleges trade secret misappropriation and seeks a declaration  
19 of ownership of certain patents and patent applications.

20 5. This Court has subject matter jurisdiction over claims 1-12 and 14-  
21 18 pursuant to at least 28 U.S.C. §§ 1331 and 1338(a), and has at least  
22 supplemental jurisdiction over claims 13 and 19-24 pursuant to at least 28  
23 U.S.C. §§ 1367(a), including because, as alleged in more detail below, they are  
24 sufficiently related to the claims over which this Court has original jurisdiction  
25 that they form part of the same case or controversy under Article III of the  
26 United States Constitution.



1 of this light is typically accomplished through a sensor that is applied to a body  
2 part such as a finger, arm, toe, forehead or ear.

3 11. Before Masimo, non-invasive measurements from the PPG were  
4 plagued by unreliability, often when the measurement was needed most, due to  
5 the person moving or having low peripheral blood flow (known as “low  
6 perfusion”). The industry had essentially given up on solving these problems,  
7 concluding they were largely unsolvable. In the medical context, clinicians had  
8 to live with the results – patient monitors gave excessive false alarms, froze  
9 their measurements for prolonged periods of time despite potential changes in  
10 the physiological parameter (e.g., oxygen saturation or pulse rate), delayed  
11 notification of alarms due to long averaging times of sensor data, produced  
12 inaccurate measurements, or were unable to obtain data on the most critical  
13 patients and babies who cannot be instructed to stay still. Masimo’s pioneering  
14 technology, known as Masimo Signal Extraction Technology (“Masimo SET”),  
15 solved this problem and dramatically improved the reliability of monitoring and  
16 reporting physiological signals derived from the PPG.

17 12. Following its initial success with Masimo SET, Masimo invested  
18 heavily in developing additional breakthrough measurement technologies, such  
19 as non-invasively measuring total hemoglobin, carboxyhemoglobin, and  
20 methemoglobin. Masimo has continued to innovate, succeeding where others  
21 have consistently failed. Masimo was the first, and remains the only, company  
22 delivering these game-changing technologies to hospitals in the United States.  
23 Use of Masimo’s technology in the clinical setting has been proven to reduce  
24 blindness in premature infants, detect congenital heart disease in infants, save  
25 lives on the general care floor and post-surgery, and improve transfusion  
26 management, while saving money.

27 13. From its inception, Masimo has continuously developed cutting-  
28 edge noninvasive patient monitoring technologies. Masimo sought and received

1 numerous U.S. patents for many of its inventions. Masimo's revolutionary  
2 technology was a key to its gaining significant market praise and penetration.  
3 After introduction into the market, many competitors, much larger than  
4 Masimo, used Masimo's technology without a license, resulting in patent  
5 infringement lawsuits that ultimately confirmed the validity of Masimo's  
6 innovations. Masimo also maintains some technology as trade secrets. Masimo  
7 also closely guards its future product and market plans. Only select employees  
8 have knowledge of and access to these guarded secrets.

9 14. Masimo's innovations also include important advances in sensor  
10 technologies that work together as part of Masimo's system and algorithms.  
11 Masimo's sensors are integral to the success of the revolutionary technologies  
12 Masimo has developed.

13 15. In 1998, Masimo spun certain technologies off into a new  
14 company, Masimo Laboratories, Inc. or "Masimo Labs," to further research and  
15 develop the technologies. The name of the company was later changed to  
16 Cercacor Laboratories Inc. or "Cercacor." Cercacor and Masimo have a cross-  
17 license agreement to facilitate confidential collaboration between the  
18 companies. Cercacor is not owned by Masimo.

19 16. Like Masimo, Cercacor is an innovator of non-invasive monitoring  
20 technologies. Cercacor is on the frontline of understanding how measuring,  
21 tracking, and analyzing physiological parameters can impact pre-diabetic and  
22 diabetic patients, sports training and performance and overall health and  
23 wellness principally in the consumer market. Cercacor continued the  
24 development that started at Masimo on non-invasive total hemoglobin (SpHb®),  
25 methemoglobin (SpMet®), and carboxyhemoglobin (SpCO®) and other non-  
26 invasive physiological parameters.

27 17. Leading hospitals around the world use Cercacor technology  
28 licensed to Masimo and sold under the name Masimo rainbow SET. Like

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.